Why was the 1980 Diamond v. Chakrabarty Supreme Court decision important for biotechnology?

Created from Britannica articles using AI. AI can make mistakes, so verify using Britannica articles.

The 1980 U.S. Supreme Court decision in Diamond v. Chakrabarty was a landmark event for the biotechnology industry because it resolved critical uncertainty regarding the legal status of genetically engineered life forms. Prior to this ruling, researchers and investors were unsure if organisms created through recombinant DNA technology could be protected by patents, as naturally occurring organisms were ineligible for such protection.1

By ruling that a "live human-made microorganism is patentable subject matter," the Court provided the legal framework necessary for companies to secure intellectual property rights over their innovations. This decision was pivotal in fueling the infant industry's first major investment boom and encouraged the formation of numerous new biotechnology firms. By establishing that these organisms could be patented, the ruling provided the commercial incentive required to transition laboratory research into the large-scale manufacturing of therapeutic proteins and other genetically engineered products.12